GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
CA2473572C
(en)
|
2002-02-01 |
2011-05-10 |
Astrazeneca Ab |
Quinazoline compounds
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
AU2003255819A1
(en)
|
2002-08-24 |
2004-03-11 |
Astrazeneca Ab |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
ATE438644T1
(de)
|
2002-12-24 |
2009-08-15 |
Astrazeneca Ab |
Chinazolinderivate
|
AU2004218412A1
(en)
|
2003-02-28 |
2004-09-16 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
AU2004293019B2
(en)
|
2003-11-19 |
2010-10-28 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
EP1732920B1
(en)
|
2004-01-05 |
2011-03-09 |
AstraZeneca AB |
Thiophene derivatives as chk 1 inhibitors
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
AU2005279045B2
(en)
|
2004-08-28 |
2009-11-26 |
Astrazeneca Ab |
Pyrimidine sulphonamide derivatives as chemokine receptor modulators
|
PL1838733T3
(pl)
|
2004-12-21 |
2012-02-29 |
Medimmune Ltd |
Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
|
CN101155800B
(zh)
|
2005-02-04 |
2012-05-23 |
阿斯利康(瑞典)有限公司 |
可用作激酶抑制剂的吡唑基氨基吡啶衍生物
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
EP2402316A1
(en)
|
2005-07-21 |
2012-01-04 |
AstraZeneca AB (Publ) |
Piperidine derivatives
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
US20090099216A1
(en)
|
2005-09-22 |
2009-04-16 |
Astrazeneca Aktiebolag A Corporation Of Sweden |
Novel adenine compound
|
US8148572B2
(en)
|
2005-10-06 |
2012-04-03 |
Astrazeneca Ab |
Compounds
|
AU2006307657B2
(en)
|
2005-10-28 |
2010-10-28 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
PT2090575E
(pt)
|
2005-11-15 |
2011-06-06 |
Array Biopharma Inc |
Inibidores de erbb
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
ATE545637T1
(de)
|
2005-12-15 |
2012-03-15 |
Astrazeneca Ab |
Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CN102558021A
(zh)
|
2006-05-26 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
MY148688A
(en)
|
2006-08-23 |
2013-05-31 |
Kudos Pharm Ltd |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
KR20090094460A
(ko)
|
2006-12-19 |
2009-09-07 |
아스트라제네카 아베 |
무스카린 수용체 길항제로서 퀴누클리디놀 유도체
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
NZ584160A
(en)
|
2007-10-04 |
2011-05-27 |
Astrazeneca Ab |
Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
|
WO2009047563A1
(en)
|
2007-10-11 |
2009-04-16 |
Astrazeneca Ab |
Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
|
CA2708871C
(en)
|
2007-12-21 |
2017-11-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
UA100400C2
(uk)
|
2008-02-06 |
2012-12-25 |
Астразенека Аб |
Похідні спіроциклічних амідів
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
AU2009252938B2
(en)
|
2008-05-27 |
2012-04-26 |
Astrazeneca Ab |
Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US9012495B2
(en)
|
2008-12-11 |
2015-04-21 |
Axcentua Pharmaceuticals Ab |
Crystalline forms of genistein
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
EP2367821B1
(en)
|
2008-12-17 |
2015-09-16 |
Merck Patent GmbH |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
AU2009336040B2
(en)
|
2008-12-18 |
2015-07-16 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
EA019647B1
(ru)
|
2009-02-10 |
2014-05-30 |
Астразенека Аб |
ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
KR20120099639A
(ko)
|
2009-10-02 |
2012-09-11 |
아스트라제네카 아베 |
호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
JP5657018B2
(ja)
|
2009-11-18 |
2015-01-21 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ベンゾイミダゾール化合物及びその使用
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
WO2011072791A1
(de)
|
2009-12-14 |
2011-06-23 |
Merck Patent Gmbh |
Inhibitoren der sphingosinkinase
|
KR20120096076A
(ko)
|
2009-12-17 |
2012-08-29 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
CN102203112B
(zh)
|
2010-01-15 |
2014-05-07 |
苏州润新生物科技有限公司 |
某些化合物、组合物及方法
|
MX2012008328A
(es)
|
2010-01-19 |
2012-08-08 |
Astrazeneca Ab |
Derivados de pirazina.
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
RU2013133846A
(ru)
|
2010-12-20 |
2015-01-27 |
Медиммьюн Лимитед |
Антитела против il-18 и их применение
|
WO2012103810A1
(en)
|
2011-02-02 |
2012-08-09 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
CN103534241B
(zh)
|
2011-02-17 |
2015-11-25 |
癌症疗法Crc私人有限公司 |
Fak抑制剂
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EA027821B1
(ru)
|
2011-07-12 |
2017-09-29 |
Астразенека Аб |
N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модулятора рецептора хемокина
|
EA029488B1
(ru)
|
2011-07-27 |
2018-04-30 |
Астразенека Аб |
Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
ES2725790T3
(es)
|
2011-08-26 |
2019-09-27 |
Neupharma Inc |
Algunas entidades químicas, composiciones, y métodos
|
US9328081B2
(en)
|
2011-09-01 |
2016-05-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
ES2655264T3
(es)
|
2012-01-28 |
2018-02-19 |
Merck Patent Gmbh |
Derivados de triazolo[4,5-d]pirimidina
|
KR20140120371A
(ko)
|
2012-02-09 |
2014-10-13 |
메르크 파텐트 게엠베하 |
Tbk1 및 ikk 저해제로서의 푸로 [3, 2 - b] - 및 티에노 [3, 2 - b] 피리딘 유도체
|
PE20141823A1
(es)
|
2012-02-09 |
2014-11-29 |
Merck Patent Gmbh |
Derivados de tetrahidro-quinazolinona
|
WO2013124026A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
|
JP6097770B2
(ja)
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
フロピリジン誘導体
|
WO2013126132A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
ES2579981T3
(es)
|
2012-03-07 |
2016-08-18 |
Merck Patent Gmbh |
Derivados de triazolopirazina
|
WO2013143663A1
(en)
|
2012-03-28 |
2013-10-03 |
Merck Patent Gmbh |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
WO2013150043A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
SI2844659T1
(sl)
|
2012-05-04 |
2016-10-28 |
Merck Patent Gmbh |
Pirolotriazinonski derivati
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
US9624264B2
(en)
|
2012-07-24 |
2017-04-18 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of arthrosis
|
EP2882746B1
(en)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
WO2014023390A2
(en)
|
2012-08-08 |
2014-02-13 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
US20160009686A1
(en)
|
2012-08-17 |
2016-01-14 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2650107C2
(ru)
|
2012-09-26 |
2018-04-09 |
Мерк Патент Гмбх |
Производные хиназолинона в качестве ингибиторов parp
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
WO2014066955A1
(en)
|
2012-11-05 |
2014-05-08 |
Lindley Robyn Alice |
Methods for determining the cause of somatic mutagenesis
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
WO2014075754A1
(en)
|
2012-11-16 |
2014-05-22 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
AU2014211962B2
(en)
|
2013-01-31 |
2017-11-16 |
Bellus Health Cough Inc. |
Imidazopyridine compounds and uses thereof
|
AU2014221010B2
(en)
|
2013-02-25 |
2018-06-14 |
Merck Patent Gmbh |
2-amino -3,4-dihydro-quinazoline derivatives and the use thereof as cathepsin D inhibitors
|
JP6409007B2
(ja)
|
2013-03-05 |
2018-10-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
EP2972394A4
(en)
|
2013-03-15 |
2016-11-02 |
Sloan Kettering Inst Cancer |
HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
EP3013424A4
(en)
|
2013-06-25 |
2017-03-29 |
University of Canberra |
Methods and compositions for modulating cancer stem cells
|
CA2921410C
(en)
|
2013-08-23 |
2023-03-28 |
Neupharma, Inc. |
Quinazoline derivatives, compositions and their use as kinase inhibitors
|
SG11201601408PA
(en)
|
2013-09-18 |
2016-04-28 |
Univ Canberra |
Stem cell modulation ii
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
US10947201B2
(en)
|
2015-02-17 |
2021-03-16 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
CA2994023A1
(en)
|
2015-08-04 |
2017-02-02 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
ES2873841T3
(es)
|
2015-08-26 |
2021-11-04 |
Gmdx Co Pty Ltd |
Métodos para detectar la recurrencia del cáncer
|
US11534451B2
(en)
|
2015-12-23 |
2022-12-27 |
Repluca Pty Ltd |
Nucleic acid oligomers and uses therefor
|
JP7341451B2
(ja)
|
2016-02-01 |
2023-09-11 |
エピアクシス セラピューティクス プロプライアタリー リミティド |
タンパク質性化合物とその利用
|
ES2906813T3
(es)
|
2016-02-15 |
2022-04-20 |
Astrazeneca Ab |
Métodos que comprenden una dosificación intermitente fija de cediranib
|
EP4104837A3
(en)
|
2016-04-15 |
2023-04-26 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
BR112019011284A2
(pt)
|
2016-12-05 |
2019-10-22 |
Apros Therapeutics Inc |
composto, composição farmacêutica, métodos de tratamento de uma condição, de hbv e de câncer, e, uso de um composto.
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
JP7202315B2
(ja)
|
2017-05-26 |
2023-01-11 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ベンズイミダゾロン由来のbcl6阻害剤
|
EP3630749B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
DK3630188T3
(da)
|
2017-05-31 |
2021-11-15 |
Amplio Pharma Ab |
Farmaceutisk sammensætning omfattende en kombination af methotrexat og novobiocin og anvendelse af sammensætningen til behandling
|
US11400160B2
(en)
|
2017-07-05 |
2022-08-02 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
RS64035B1
(sr)
|
2017-08-01 |
2023-04-28 |
Merck Patent Gmbh |
Derivati tiazolopiridina kao antagonisti receptora adenozina
|
EP3668882A1
(en)
|
2017-08-18 |
2020-06-24 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
JP7287952B2
(ja)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
|
AU2018320672B2
(en)
|
2017-08-21 |
2023-09-07 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
KR20200104291A
(ko)
|
2017-11-06 |
2020-09-03 |
랩트 테라퓨틱스, 인크. |
항암제
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
WO2019136514A1
(en)
|
2018-01-15 |
2019-07-18 |
University Of South Australia |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
US10683280B2
(en)
|
2018-01-26 |
2020-06-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
JP2021512893A
(ja)
|
2018-02-08 |
2021-05-20 |
ニューファーマ,インク. |
特定の化学物質、組成物、および方法
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
MX2020010805A
(es)
|
2018-04-13 |
2021-01-29 |
Cancer Research Tech Ltd |
Inhibidores de bcl6.
|
EP3784233B1
(en)
|
2018-04-27 |
2024-06-05 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
US10857153B2
(en)
|
2018-06-04 |
2020-12-08 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
CA3099776A1
(en)
|
2018-09-18 |
2020-03-26 |
Suzhou Zanrong Pharma Limited |
Quinazoline derivatives as antitumor agents
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
MX2021003508A
(es)
|
2018-10-25 |
2021-05-27 |
Merck Patent Gmbh |
Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
|
AU2019363662A1
(en)
|
2018-10-25 |
2021-03-25 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN114729354A
(zh)
|
2018-12-25 |
2022-07-08 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
US20230085408A1
(en)
|
2019-04-05 |
2023-03-16 |
STORM Therapeutics Ltd. |
Mettl3 inhibitory compounds
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
CN114555593A
(zh)
|
2019-09-20 |
2022-05-27 |
伊迪亚生物科学有限公司 |
作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
AU2020394867A1
(en)
|
2019-12-02 |
2022-05-26 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as METTL3 inhibitors
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
CN117222435A
(zh)
|
2021-05-03 |
2023-12-12 |
默克专利有限公司 |
HER2靶向Fc抗原结合片段-药物缀合物
|
KR20220156448A
(ko)
|
2021-05-17 |
2022-11-25 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|